Ashok Muthukrishnan, MD, MS, addresses the recent FDA approval of lutetium 177Lu vipivotide tetraxetan and looks to the potential of radioimmunotheranostics on the horizon.
Sanandan Ojha
Advertisement
Articles by Sanandan Ojha
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Alignment Reached on Phase 3 Design for RGT-61159 in ACC
2
Sofetabart Mipitecan Elicits Responses Across FRα Levels in Ovarian Cancer
3
FDA Grants Traditional Approval to Pembrolizumab in TMB-High Solid Tumors
4
FDA Grants Fast Track Status to SBE303 in Urothelial Cancer
5